Dr. Bernhard H. Weigl is Senior Platform Manager and Technical Expert, Flow-Based Diagnostics at Intellectual Ventures/Global Good, and the former Director of the National Institutes of Health-funded Center for Point-of-Care Diagnostics for Global Health. Intellectual Ventures/Global Good is an organization led and funded directly by Bill Gates that develops health technologies for low-resource settings. Dr. Weigl heads the organization’s development of in-vitro diagnostic technologies. Previously, Dr. Weigl led the In-Vitro Diagnostics Group at PATH technologies, where he oversaw global health diagnostics programs funded by a variety of sources such as NIAID and NIBIB, the Grand Challenges program of the Bill and Melinda Gates Foundation, USAID, and the PATH Health Innovation Portfolio. Dr. Weigl is also an Affiliate Professor at the University of Washington Department Of Bioengineering. Before joining Intellectual Ventures/Global Good, both at the University of Washington and at Micronics, Inc. (Redmond, Washington, where he was a scientific cofounder), Dr. Weigl led teams that developed both instrument-based and stand-alone microfluidic medical diagnostic disposables. His scientific interests include microfluidics as well as any diagnostic platforms that allow simplification and integration of previously complex assays. As chronic diseases, and especially diabetes, are emerging as a major health threat in developing countries, he is now focusing specifically on their diagnosis, screening, and treatment. He received his M.Sc and Ph.D. from Karl-Franzens-University Graz and has completed post-doctoral studies at the University of Southampton and the University of Washington. He has authored more than 90 scientific papers and is an inventor on over 70 US patents and patent applications.
JTEHM, Articles, Published ArticlesMore Than Just Accuracy: A Novel Method to Incorporate Multiple Test Attributes in Evaluating Diagnostic Tests Including Point of Care Tests
Current frameworks for evaluating diagnostic tests are constrained by a focus on diagnostic accuracy, and assume that all aspects of the testing process and test attributes are discrete and equally important. Determining the balance between the benefits and harms associated... Read more
Posted on 14 JUN 2016